ArticleCellular and molecular life sciences : CMLS2026
Circ_0001428 regulates erythropoiesis and γ-globin expression via activating the ATF4-BCL11A axis in β-thalassemia.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
β-Thalassemia is a chronic hemolytic anemia caused by mutations in the β-globin gene. Increasing studies have shown that circular RNA (circRNA) plays a key role in abnormal hematopoiesis. Circ_0001428 is formed by circularization of the beta-mannosidase gene. However, little is known about the biological function of circ_0001428 in β-thalassemia. Circ_0001428 was selected from two circRNA microarrays (GSE241141 and GSE196682) of β-thalassemia, and expression levels of circ_0001428, miR-32-3p, miR-325-3p, γ-globin, activating transcription factor 4 (ATF4) and B-cell lymphoma/leukemia 11 A (BCL11A) were validated in 30 patients with β-thalassemia and 30 healthy controls. Cell proliferation, apoptosis, cell cycle, and erythroid differentiation were evaluated using stable knockdown or overexpression of circ_0001428. Fluorescence in situ hybridization, dual-luciferase reporter, and Western blots were performed to confirm interactions between circ_0001428, miR-32-3p/miR-325-3p, and ATF4. Circ_0001428 was downregulated in β-thalassemia patients compared to controls, promoted cell proliferation, decreased cell apoptosis, and inhibited terminal erythroid differentiation and γ-globin production. Mechanistically, circ_0001428 functions as a sponge for miR-32-3p and miR-325-3p to promote ATF4 expression, thereby activating BCL11A expression. Additionally, rescue experiments confirmed that circ_0001428 regulated erythropoiesis and γ-globin expression via promoting the ATF4-BCL11A axis by binding with miR-32-3p/miR-325-3p. Our findings reveal, for the first time, the important role of circ_0001428 in regulating erythropoiesis and γ-globin expression in β-thalassemia. The circ_0001428/miR-32-3p and miR-325-3p/ATF4/BCL11A/γ-globin signaling pathway may be a potential therapeutic target in β-thalassemia, especially for fetal hemoglobin modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.